explore -WSS

explore

author：entertainment 2025-09-29 01:06:31 - browse：91418

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Pregnancy discrimination could be enabled by AI

WSS

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Leukemia patients are helped by Syndax's new type of therapy

Teach medical students about patients with intellectual disabilities

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

FDA early review: GLP

hotspot

explore

leisure time

At least 13 dead in Texas as scorching temps continue

Profiling embryos to choose those with higher IQs is almost a reality

Anesthesiologist group: stop taking Ozempic before surgery

Chemotherapy shortages won’t get better under Biden’s latest plan

Apple is now the first public company to be valued at $3 trillion

SCOTUS to consider access to abortion pill mifepristone

Medical records are filled with copy

Americans' trust in science, scientist continues decline: Report

In Memoriam: Notable people who died in 2023

CMS should re

entertainment

Arena BioWorks launches in Cambridge to speed drug discovery

Medicare Advantage coverage denials need scrutiny, senators say

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Life science postdocs should get big pay hike, NIH panel says

Does Paxlovid work in people vaccinated against Covid

Merck to acquire Harpoon Therapeutics for $680 million

Wikipedia

explore

hotspot

focus